SynthesisEuropean journal of nuclear medicine and molecular imaging2011
Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.
Synthesis in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Rare Acute Polyarticular Gout Disease Detected withMolecular imaging and radionuclide therapy · 2025Article
- Beyond the Surface: Nutritional Interventions Integrated with Diagnostic Imaging Tools to Target and Preserve Cartilage Integrity: A Narrative Review.Biomedicines · 2025Review
- Role of PET/CT in diagnosing and monitoring disease activity in rheumatoid arthritis: a review.Annals of nuclear medicine · 2024Review
- An update on the unparalleled impact of FDG-PET imaging on the day-to-day practice of medicine with emphasis on management of infectious/inflammatory disorders.European journal of nuclear medicine and molecular imaging · 2020Article
- Applications of PET-Computed Tomography-Magnetic Resonance in the Management of Benign Musculoskeletal Disorders.PET clinics · 2019Review
- Potential of PET-MRI for imaging of non-oncologic musculoskeletal disease.Quantitative imaging in medicine and surgery · 2016Review
- Increased 18F-FDG uptake suggests synovial inflammatory reaction with osteoarthritis: preliminary in-vivo results in humans.Nuclear medicine communications · 2015Article
- Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis.Nature reviews. Rheumatology · 2012Review
- Current imaging strategies in rheumatoid arthritis.American journal of nuclear medicine and molecular imaging · 2012Article
- Non-FDG PET in oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011Review
- Semi-quantitative analysis ofWorld journal of nuclear medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessing joint disorders has been a relatively recent and evolving application of 18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging. FDG is taken up by inflammatory cells, particularly when they are active as part of an ongoing inflammatory process. Hence FDG PET has been employed to assess a wide array of arthritic disorders. FDG PET imaging has been investigated in various joint diseases for diagnostic purposes, treatment monitoring, and as a prognostic indicator as in other disorders. In some of the diseases the ancillary findings in FDG PET have provided important clues about the underlying pathophysiology and pathogenesis processes. While substantial promise has been demonstrated in a number of studies, it is clear that the potential utility of PET in this clinical realm far outweighs that which has been established to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.